Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Net Income (Common)
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Net Income (Common)
¥1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Net Income (Common)
¥2.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥4.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥4.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Net Income (Common)
¥755.6m
|
CAGR 3-Years
36%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
1B
CNY
Based on the financial report for Sep 30, 2023, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income (Common) amounts to 1B CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
19%
Over the last year, the Net Income (Common) growth was -9%. The average annual Net Income (Common) growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 10% over the past three years , 19% over the past five years .